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In the treatment of acute ischemic stroke (AIS), vessel recanalization correlates with
improved functional status and reduced mortality. Mechanical neurothrombectomy
achieves a higher likelihood of revascularization than intravenous thrombolysis (IVT),
but there remains significant discrepancy between rates of recanalization and rates
of favorable outcome. The poor neurological recovery among some stroke patients
despite successful recanalization confirms the need for adjuvant therapy, such as
pharmacological neuroprotection. Prior clinical trials of neuroprotectant drugs failed
perhaps due to inability of the agent to reach the ischemic tissue beyond the occluded
artery. A protocol that couples mechanical neurothrombectomy with concurrent delivery
of a neuroprotectant overcomes this pitfall. Activated protein C (APC) exerts pleiotropic
anti-inflammatory, anti-apoptotic, antithrombotic, cytoprotective, and neuroregenerative
effects in stroke and appears a compelling candidate for this novel approach.
Keywords: activated protein C (APC), endovascular restorative neurosurgery, mechanical neurothrombectomy,
neuroprotection, neurorestoration, stroke, thrombolysis
Abbreviations: APC, Activated protein C; AIS, Acute ischemic stroke; BBB, Blood brain barrier; CNS, Central nervous
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RESCUE, Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy; MCAO, Middle cerebral artery
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Stroke is the second leading cause of death worldwide and the
number one cause of disability in the United States (Mozaffarian
et al., 2015). Despite extensive research into the pathophysiology
underlying acute ischemic stroke (AIS), intravenous tissue
plasminogen activator (IV tPA) remains the only drug approved
by the United States Food and Drug Administration (FDA) for
its treatment. However, the time window for IV tPA eligibility
is short, and there are contraindications for its use (Jauch et al.,
2013). Furthermore, the (mis)perception of marginal utility, high
risk of intracerebral bleeding, and/or high liability associated
with its administration curtails the enthusiasm ofmany providers
(SoRelle, 2013). As a result of these and other factors, only about
5% of AIS patients receive IV tPA (Jauch et al., 2013; Schwamm
et al., 2013; Mozaffarian et al., 2015). Among those treated, rates
of recanalization and good neurological outcome vary based on
the site and size of the affected vessel, but can be as low as 5%
for proximal occlusion of the internal carotid or basilar arteries
(Bhatia et al., 2010). Clearly, a need exists for more effective
reperfusion and neuroprotective strategies.
Mechanical neurothrombectomy has recently emerged as a
promising approach to AIS therapy. The current generation of
aspiration and stent retrieval devices achieves recanalization in
the majority of patients (Table 1; Penumbra Pivotal Stroke Trial
Investigators, 2009; Berkhemer et al., 2015; Nogueira et al., 2012;
Saver et al., 2012, 2015a; Almekhlafi et al., 2014; Campbell et al.,
2015; Goyal et al., 2015). Detailed analysis of adverse events
and safety data confirms that neurothrombectomy procedures
can be performed with minimal morbidity and mortality
(Akins et al., 2014). Nonetheless, the likelihood of functional
independence following neurothrombectomy (14–58%) remains
poor compared with rates of recanalization (60–90%; Table 1).
The disparity between the rates of recanalization and
rates of neurological recovery underscores the need for
adjunctive therapy, such as pharmacological neuroprotection.
Myriad preclinical studies and human trials with potential
neuroprotective agents have been reported, yet none has proven
unequivocally efficacious and none has achieved FDA approval
(Ginsberg, 2009; Tymianski, 2013). Among the reasons cited for
the failure of clinical trials in the face of encouraging animal
data is the delayed time to administration, but even prehospital
delivery of magnesium, given an average of just 45 min after
symptom onset, failed to show benefit in a well-organized
trial (Saver et al., 2015b). Another plausible explanation for
the failed translation from bench to bedside is that the agent
cannot reach the ischemic tissue due to lack of perfusion.
When given systemically, neuroprotective agents must rely on
collateral flow to ischemic tissue as they cannot traverse the
occluded artery, but such collateral flow may be insufficient for
adequate drug delivery. This provides impetus for a strategy
coupling revascularization with the ancillary administration of a
neuroprotective drug.
In this article, we review the foundation for an ongoing
clinical trial coupling neurothrombectomy with adjunctive
delivery of an activated protein C (APC) analog. APC confers
pleiotropic benefits, such as stabilizing blood brain barrier
(BBB) integrity, preventing thrombosis, enhancing fibrinolysis,
promoting neuroprotection, attenuating inflammation, and
facilitating neuroregeneration (Griffin et al., 2002, 2015; Zlokovic
and Griffin, 2011). It represents a novel multiple-actionmultiple-
target approach that ameliorates all facets of the pathogenic
triad (consisting of vascular damage, neuronal injury, and
neuroinflammation) that characterizes stroke and many other
central nervous system (CNS) disorders (Zlokovic and Griffin,
2011). Since first report of the anti-inflammatory, cytoprotective,
and antithrombotic properties of APC in stroke (Shibata et al.,
2001), it has progressively fulfilled Stroke Therapy Academic
Industry Roundtable (STAIR) criteria for drug development
(Zlokovic and Griffin, 2011). The preclinical safety and
pharmacokinetic profile of APC has been well characterized in
mice and monkeys (Williams et al., 2012). A phase I safety
study in normal human subjects has shown that high dose
bolus regimens of modified APC are well-tolerated (Lyden et al.,
2013), and a multicenter phase II dose-escalation clinical trial of
intravenous administration for AIS (NCT02222714, NN104) is
currently in progress (ZZ Biotech LLC, 2015).
Limitations of Pharmacologic
Thrombolysis
Data from intravenous thrombolysis (IVT) trials serve as
the benchmark against which recanalization therapies such as
neurothrombectomy are measured. Several small randomized
trials of IV tPA suggested its safety efficacy in AIS (Mori
et al., 1992; Haley et al., 1993), but large, randomized trials
of another thrombolytic drug, intravenous streptokinase, were
stopped early because of unacceptable rates of symptomatic
intracranial hemorrhage (sICH; Donnan et al., 1995; Hommel
et al., 1995).
The seminal National Institute of Neurological Disorders
and Stroke (1995) trial reported favorable results that formed
the basis for FDA approval of IV tPA in AIS. In this study,
subjects were randomly assigned to receive either 0.9 mg/kg IV
tPA (maximum 90 mg) given within 3 h of symptom onset or
placebo. Due to the Phase 2 design of this pilot study, there were
numerous exclusion criteria such as systolic blood pressure above
185 mm Hg or diastolic blood pressure above 110 mm Hg, prior
stroke or head trauma within 3 months, major surgery within
14 days, history of intracranial bleed, anticoagulant use, platelet
counts below 100,000 mm3, blood glucose concentration above
400 mg per deciliter, and others. The median National Institutes
of Health Stroke Scale (NIHSS) score was 14 (range 1–37). There
was a powerful and statistically significant benefit shown: at 3
months, the odds ratio for favorable outcome was 1.7 in the tPA
group as compared with placebo. There was also a 12% absolute
increase and 32% relative increase in the number of patients with
minimal or no disability (Barthel Index 95–100) in the tPA group.
Although there was no statistically significant difference between
the group given tPA and that given placebo in the percentage
of patients who showed a 4-point neurological improvement at
24 h (47 vs. 39% respectively, p = 0.06), using any other cut
point yielded a highly significant benefit at 24 h (Haley et al.,
1997). In addition, a long-term benefit 1 year later was observed
for the tPA group using a global test statistic that represents
a composite of other scales, including modified Rankin score
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(mRS). sICH within 36 h after stroke onset occurred in 6.4% of
patients given tPA but only 0.6% of patients given placebo (p <
0.001). Mortality at 3 months was 17% in the tPA group and 21%
in the placebo group (p = 0.30).
The benefit of IVT was confirmed in several subsequent,
independent clinical trials (Hacke et al., 2008; Group et al., 2012).
An ensuing meta-analysis of nine randomized trials confirms
the robust benefit of IV tPA for AIS, with earlier administration
associated with bigger proportional gain (Emberson et al., 2014).
Among patients treated within 3 h, good outcome occurred
in 259 (32.9%) of 787 patients given IV tPA vs. 176 (23.1%)
of 762 who received control (OR 1.75, 95% CI 1.35–2.27).
Treatment instituted after 3 h but before 4.5 h resulted in
good outcome for 485 (35.3%) of 1375 patients vs. 432 (30.1%)
of 1437 (OR 1.26, 95% CI 1.05–1.51). Delayed treatment
beyond 4.5 h was not associated with statistically significant
benefit.
In the NINDS trial, the size and location of the occluded vessel
was not reported, as there was no time for vascular imaging.
Stroke subtype (e.g., lacunar vs. large vessel) was determined
using accepted clinical definitions. Similarly, there could be no
data about recanalization. Subsequent studies have found that
rates of recanalization with IV tPA alone can be as low as
5–10% for proximal large vessel occlusion (LVO), but much
higher for more distal occlusions (Bhatia et al., 2010). Therefore,
it is likely that the trials of IV tPA conducted without vessel
imaging may have included patients with small vessel stroke
and thus may overestimate any potential benefit to patients
with LVO.
Due to these low rates of recanalization with LVO, various
exclusion criteria, the short time window for benefit, the modest
rates of good outcome, and other limitations of IV tPA,
investigative efforts have focused on alternative revascularization
strategies for LVO, including intra-arterial therapy (IAT). Such
approaches include in situ delivery of thrombolytic drugs or
other pharmacologic agents as well as neurothrombectomy.
Currently, IAT is performed in patients who fail to recanalize
after IV tPA or those who are ineligible for IV tPA on the basis of
time or other exclusion criteria.
Local delivery of intra-arterial thrombolytics in animal
models and small case series of human subjects suggested the
safety and feasibility of this approach (Jadhav and Jovin, 2013),
leading to subsequent randomized clinical trials (RCTs) such as
the Prolyse in Acute Cerebral Thromboembolism (PROACT)
I and II trials (del Zoppo et al., 1998; Furlan et al., 1999),
which studied the intra-arterial delivery of recombinant pro-
urokinase (rpro-UK) among patients with proximal middle
cerebral artery occlusion (MCAOs: M1 or M2 segments)
treated within 6 h of stroke onset. All patients also received
adjunctive intravenous heparin, which likely contributed to rates
of recanalization and/or reperfusion hemorrhage. Recanalization
was assessed using the Thrombolysis in Myocardial Infarction
(TIMI, 1985) score, which ranges from 0–3. Using an IAT
dose of 6 mg rpro-UK and high vs. low doses of iv
heparin, PROACT I proved superior rates of recanalization
with thrombolytic (58%) than with control (15%; del Zoppo
et al., 1998). Hemorrhagic transformation causing neurological
deterioration within 24 h of treatment occurred in 15.4% of
the rpro-UK group and 7.1% of the placebo group, but the
difference was not statistically significant due to small sample
size. Both recanalization and hemorrhage frequencies were
influenced by heparin dose. Therefore, in an effort to increase
recanalization while decreasing sICH, PROACT II used an
IAT dose of 9 mg pro-UK and low dose IV heparin. This
study also demonstrated superior rates of recanalization with
thrombolytic (66%) than with control (18%; Furlan et al.,
1999). Rates of functional independence (mRS 0–2) were also
higher among the rpro-UK group (40%) than control (25%).
Hemorrhagic transformation causing neurological deterioration
within 24 h of treatment occurred in 10% of the rpro-
UK group and 2% in the control group. Overall rates of
hemorrhage, however, were as high as 68% at 10 days in
the rpro-UK cohort, emphasizing that many hemorrhages
within the infarcted territory do not produce incremental
deficit. Ultimately, rpro-UK IAT was not pursued further for
AIS.
Following on the promising results of PROACT, the IMS
Study Investigators (2004) and IMS II Trial Investigators
(2007) trials assessed a combined intravenous and intra-arterial
approach to recanalization. In these prospective open label
studies, reduced dose (0.6 mg/kg, 60 mg maximum) IV tPA was
given within 3 h, followed by adjunctive IAT using up to 22 mg
of tPA delivered at the site of occlusion. Compared with age-
and severity-matched historical controls of IV tPA alone from
the NINDS trial, the suggestion of improved outcomes with the
combined IV and IA approach formed the rationale for IMS-III,
a subsequent phase III RCT (Broderick et al., 2013).
Mechanical Neurothrombectomy: Lessons
Learned
In 2004, the Merci device (Stryker Neurovascular, Kalamazoo,
MI, USA) became the first mechanical clot retriever to receive
FDA clearance for AIS. The Merci system consists of a
nitinol wire with a helical terminus that is deployed distal to
the occlusion and then withdrawn proximally after engaging
thrombus within its corkscrew structure. A balloon integrated
into the guiding catheter is inflated during this process in
order to arrest anterograde flow, thereby mitigating against
the dislodgement of distal emboli. The Mechanical Embolus
Removal in Cerebral Ischemia (MERCI) trial was a single
arm, prospective, multicenter study large vessel stroke treated
within 8 h of symptom onset who were ineligible for IV tPA
(Smith et al., 2005). Recanalization (TIMI 2–3) was achieved
in 46% of patients. Favorable outcome at 90 days (mRS 0–2)
occurred in 27.7% of subjects overall, but there was a significant
difference between those with recanalization (46%) and those
without (10.4%). Similarly, overall mortality at 90 days was
43.5% overall but was better for those with recanalization
(31.8%) than those without (54.2%). sICH was observed in
7.8%.
The Multi-MERCI trial was also a single arm, prospective,
multicenter study of AIS patients with LVO treated within 8 h
of stroke onset (Smith et al., 2008). However, some patients also
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received adjunctive IV tPA. In addition to the use of a newer
generationMerci device, investigators could also perform salvage
therapy with intra-arterial thrombolytic infusion. This approach
increased the recanalization (TIMI 2–3) rate from 55% with
the retriever alone to 68% overall. The rate of good outcome
(mRS 0–2) at 90 days, however, remained disparately low at 36%.
Mortality was 34% and sICH occurred in 9.8%.
In 2007, the Penumbra system (Penumbra Inc., Alameda,
CA, USA) became the second FDA approved device for
mechanical removal of thrombus in AIS. Unlike the Merci
retriever, the Penumbra device does not require traversal of
the clot and instead applies aspiration force to its proximal
surface. Theoretically, this might reduce the incidence of distal
emboli caused during the procedure and thus improve functional
outcome. The Penumbra Pivotal Stroke Trial Investigators
(2009) was a single-arm, prospective multicenter study of
AIS patients with LVO who were either ineligible for or
refractory to IV tPA. The device achieved an impressive
revascularization rate of 81.6% using the thrombolysis in
cerebral ischemia (TICI) scale, an analog to the TIMI rating
(Higashida et al., 2003). However, only 25% had mRS 0–2
at 90 days, while another 33% died. The sICH rate was
11.2%.
Subsequent efforts at revascularization in AIS focused on stent
technology, borrowing from the rich experience of these devices
in the treatment of acutemyocardial ischemia. Indeed, placement
of implantable stents in AIS achieves high rates of recanalization,
but it requires peri- and post-procedural antiplatelet therapy
to prevent in-stent thrombosis, thus heightening the risk of
reperfusion hemorrhage (Levy et al., 2009). In response, two
new retrievable stents (‘‘stentrievers’’) were developed to exploit
their efficacy in revascularization while eliminating the need to
implant them in situ. As these devices are deployed within the
clot, their struts engage the thrombus. When the stentriever is
withdrawn, the entrapped clot is extracted from the body.
The first of these devices to gain FDA approval in 2012 was
the Solitaire stent (Medtronic Inc., Minneapolis, MN, USA).
In a study that directly compared its performance with that
of the Merci device, the Solitaire yielded superior rates of
recanalization (61% vs. 24%), mRS 0–2 (58% vs. 33%), sICH
(2% vs. 11%), and mortality (17% vs. 38%; Saver et al., 2012).
Detailed analysis of adverse events and safety data showed
that minimal morbidity and mortality were attributable to the
neurothrombectomy procedure itself (Akins et al., 2014). A
subsequent single-arm registry confirmed these favorable results
(Almekhlafi et al., 2014). The Trevo stentriever (Stryker Inc.,
Kalamazoo, MI, USA) became the fourth (and currently last)
device to gain FDA approval for mechanical clot removal in AIS.
In a study that directly compared its performance with that of
the Merci device (Nogueira et al., 2012), the Trevo also yielded
superior rates of recanalization (86% vs. 60%), mRS 0–2 (40% vs.
21.8%), and sICH (7% vs. 9%), but not mortality (33% vs. 24%,
NS).
Although these single arm studies or randomized
comparisons of various neurothrombectomy devices suggested
progress compared with historical controls from IV thrombolysis
trials, direct comparisons were lacking, and it remained
uncertain whether or not the higher rates of recanalization
achieved with IAT would translate into improved clinical
outcome. Three subsequent RCTs failed to support the
superiority of IAT over IV tPA alone (Broderick et al., 2013;
Ciccone et al., 2013; Kidwell et al., 2013). However, all of them
were subject to methodological flaws that call their validity into
question.
The SYNTHESIS trial randomly assigned AIS patients less
than 4.5 h from symptom onset to endovascular therapy (intra-
arterial thrombolysis with tPA, mechanical clot disruption or
retrieval, or combinations thereof) or standard dose IV tPA
(Ciccone et al., 2013). The rates of good outcome (mRS 0–2) were
comparable between IAT and IVT (42% vs. 46%) as were rate
of sICH (6% vs. 6%) and mortality (8% vs. 6%), respectively. Of
note, vessel imaging and confirmation of LVO pre-enrollment
were not reported, and almost half of the patients had NIHSS
<11, making LVO less likely in those subjects. Similarly, the
locations of vessel occlusion and rates of LVO or recanalization
were also not reported. Few IAT patients actually received
neurothrombectomy, and the newer generation devices were
rarely employed. Furthermore, IAT was instituted 1 h later (3.75
vs. 2.75 h) than IVT on average. Lastly, the withholding of IV tPA
in the IAT group represents a departure from real world practice
and likely contributed to lower rates of good clinical outcome in
this group.
The IMS III trial randomly assigned eligible patients who
received IV tPA within 3 h of symptom onset to receive
additional IAT or IVT alone (Broderick et al., 2013). The
trial was terminated for reasons of futility when a prespecified
stopping rule was triggered, after it was demonstrated that
rates of mRS 0–2 at 90 days were similar in the IAT and
IVT groups (40.8% vs. 38.7%, respectively). Rates of sICH
(6.2% vs. 5.9%) and mortality at 90 days (19.1% vs. 21.6%)
were also similar. As with the SYNTHESIS trial, however, IMS
III suffers from several criticisms that call into question its
relevance to contemporary practice. First of all, vessel imaging
and confirmation of LVO were not required. In the IAT group,
many received the lower dose of IV tPA as per the prior IMS
trials (0.6 mg/kg, 60 mg max) while only some received full dose
(0.9 mg/kg, 90 mg maximum). Since the trial was conducted
over 6 years, the nature of IAT varied according to available
technology but mostly consisted of intra-arterial thrombolysis
(80%) followed by use of earlier generation neurothrombectomy
devices such as Merci (28%) or Penumbra (16%), while only
1.5% of patients were treated with stentrievers. Thus, rates
of reperfusion according to the standard metric of TICI 2b-
3, ranged from 38–44% according to location. Lastly, as with
SYNTHESIS, there was significant delay in the initiation of IAT
of up to more than 1 h.
In retrospective analysis of the prior trials, outcomes were
generally worse among patients with established infarction on
initial imaging. The Mechanical Retrieval and Recanalization
of Stroke Clots Using Embolectomy (MR RESCUE) sought
to assess the benefit of IAT in the presence of a penumbra
of vulnerable tissue surrounding a small core infarct, based
on the premise that salvage of this area through reperfusion
might improve clinical outcome (Kidwell et al., 2013). The
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trial randomly assigned patients within 8 h of symptom onset
to receive neurothrombectomy (with Merci or Penumbra) or
standard care. Revascularization was achieved in 67% of the IAT
group. However, at 3 months, rates of good outcome among the
IAT and medical therapy groups were similarly poor (18.8% vs.
20.4% overall) whether or not a penumbral pattern was present
(21% vs. 26%, 17% vs. 10%, respectively), as were those for
sICH and death (Table 1). Criticisms of this trial include the
long delay to initiation of IAT and the use of first generation
neurothrombectomy devices.
Seeking to redress many of the problems of the trials showing
no benefit of IAT over IVT alone, 4 RCTs were recently
conducted, all proving the superiority of IAT when LVO is
confirmed, newer generation devices are employed, appropriate
adjunctive therapy is administered, and attention is focused on
timely intervention (Berkhemer et al., 2015; Campbell et al., 2015;
Goyal et al., 2015; Saver et al., 2015a).
The Multicenter Randomized Clinical Trial of Endovascular
Treatment for AIS in the Netherlands (MR CLEAN) trial
randomly assigned patients to intra-arterial treatment plus
usual care or usual care alone (Berkhemer et al., 2015).
All patients had proximal arterial occlusion in the anterior
circulation confirmed by vessel imaging. Prior to enrollment,
89% of patients received IV tPA. Retrievable stents were used
in 81.5% of patients assigned to interventional treatment,
and TICI 2a or greater recanalization was achieved in
81.6% of patients. The rate of functional independence
(mRS 0–2) with intervention (32.6%) was greater than
that of control (19.1%) but was still comparatively low,
reinforcing the unmet needs in AIS care. There were no
significant differences in the occurrence of symptomatic
intracerebral hemorrhage (7.7% vs. 6.4%) or 30-day morality
(18.4% vs. 18.9%) in the interventional and control arms,
respectively.
The Endovascular Treatment for Small Core and Anterior
Circulation Proximal Occlusion with Emphasis on Minimizing
CT to Recanalization Times (ESCAPE) trial compared IAT
plus standard care vs. standard care alone in AIS patients with
a small infarct core, proximal intracranial arterial occlusion,
and moderate-to-good collateral circulation (Goyal et al., 2015).
Importantly, patients up to 12 h after symptom onset were
included. The study was terminated early due to the favorable
rates of good outcome (mRS 0–2) in the interventional group
(53%) vs. control (29.3%). Recanalization (TICI 2b or greater)
occurred in 72.4%. sICH occurred in 3.6% of the intervention
group and 2.7% of control, and mortality was reduced in the
interventional group compared with control (10.4%, vs. 19.0%,
respectively).
The Extending the Time for Thrombolysis in Emergency
Neurological Deficits—Intra-Arterial (EXTEND-IA) trial
studied AIS patients in whom CT perfusion confirmed the
presence of salvageable brain and small infarct core (Campbell
et al., 2015). All received standard dose IV tPA. Half were
randomized to IVT alone while the other half was randomized
to IAT using the Solitaire device. Reperfusion (assessed on CT
imaging and thus on a different scale than TICI) was 100% in the
Solitaire arm compared with 37% in the tPA-only group. Good
functional outcome of mRS 0–2 was also more likely in the IAT
group (71%) than the control (40%). Rates of sICH (0% vs. 6%)
and mortality (9% vs. 20%) were also better for the IAT group.
The Solitaire With the Intention For Thrombectomy as
Primary Endovascular Treatment (SWIFT PRIME) Trial is the
most recently completed RCT of IAT vs. IVT alone for AIS
(Saver et al., 2015a). All patients received full dose IV tPA. Using
the Solitaire device, the IAT arm demonstrated an 88% rate of
recanalization. Good functional outcome (mRS 0–2) occurred in
60.2% of the interventional group compared with 35.5% in the
IV tPA arm. The rate of sICH (1%) in the Solitaire group was
exceedingly low.
Collectively, these studies confirm that the newest generation
of neurothrombectomy devices can achieve recanalization in
the vast majority of patients. Even when neurothrombectomy
is performed expeditiously among AIS patients with small
infarct cores, however, the rate of good clinical outcomes is
comparatively poor (Table 1). In real world settings outside the
idealized circumstances of a clinical trial, clinical outcomes are
likely to be even worse, thus reinforcing the need for adjunctive
neuroprotective therapy, such as APC infusion.
Overview of Activated Protein C
APC is an endogenous serine protease that favorably regulates
multiple pathways within different cell types comprising
the neurovascular unit, including neurons, vascular cells
(endothelium, pericytes, and vascular smooth muscle cells),
and glia (astrocytes, microglia, and oligodendroglia), all of
which contribute to disease initiation and/or progression in AIS
(Zlokovic and Griffin, 2011). APC is generated as part of the
physiologic protective response to cerebral ischemia (Griffin
et al., 2002). Further evidence of the importance of APC in
stroke comes from prospective observational data suggesting
that circulating levels of its zymogen precursor, protein C, are
inversely related to the incidence of ischemic stroke (Folsom
et al., 1999).
Protein C is a plasma zymogen that is synthesized in the
liver and proteolytically activated by thrombin when bound to
the endothelial protein C receptor (EPCR). The EPCR mediates
many subsequent actions of APC (Domotor et al., 2003; Zlokovic
and Griffin, 2011; Griffin et al., 2015) including transport across
the BBB into the extravascular tissue (Deane et al., 2009) and
activation of several cell signaling pathways, which ultimately
affects the expression of hundreds of proteins (Griffin et al.,
2015).
Conversely, dissociation of APC from EPCR allows its
interaction with circulating clotting factors. By cleaving activated
cofactors Va and VIIIa to yield the inactivated factors Vi and
VIIIi, APC exerts potent antithrombotic effects. Replacement
of a cluster of positively charged residues with neutral amino
acids on the top surface of the APC protease domain near
the C-terminus generates variants with reduced anticoagulant
activity, but preserves the cell-signaling actions mediated by
its N-terminus. For instance, substitution of three consecutive
lysine residues 191–193 by alanine (3K3A-APC) causes loss
of >92% of anticoagulant activity in human plasma and in
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monkeys compared with wild type APC (Zlokovic and Griffin,
2011; Williams et al., 2012). Such analogs are likely to prove
favorable for therapeutic application in conditions where the
cytoprotective properties aremaintained, while the risk of serious
bleeding is diminished (Williams et al., 2012).
EPCR-bound APC activates a family of G-protein coupled
protease-activated receptors (PARs), including PAR1 (Domotor
et al., 2003). The latter can also be activated by thrombin, but each
ligand triggers divergent intracellular signaling cascades (biased
agonism; Griffin et al., 2015). Whereas thrombin-mediated
activation of PAR 1 leads to disruption of the BBB, vascular
leakage, neurotoxicity, apoptosis, and neuroinflammation, APC-
mediated activation of PAR1 produces the opposite effects.
APC-induced biased signaling following PAR-1 activation is
required for neuroprotective actions of APC (see Figure 1).
These multiple downstream effects of APC have been reviewed
elsewhere (Griffin et al., 2002, 2015; Zlokovic and Griffin, 2011)
and are summarized below.
FIGURE 1 | Neuroprotective direct effects of APC on cells involves
receptors endothelial protein C receptor (EPCR) and PAR-1. The cellular
receptors EPCR and PAR1 are required for APC’s beneficial effects on many
types of brain cells. These activities include APC-mediated anti-apoptotic
activities, anti-inflammatory activities, protection of endothelial barrier
functions, and alterations of gene expression profiles. One or more of these
activities plus other yet to be defined signaling actions are required for APC’s
multiple neuroprotective activities (Zlokovic and Griffin, 2011). This paradigm in
which EPCR-bound APC activates PAR-1 to initiate biased signaling (Griffin
et al., 2015) is supported by many in vitro and in vivo data (Zlokovic and
Griffin, 2011; Griffin et al., 2015). Localization of APC signaling in the
caveolin-1 rich microdomains (caveolae) may help differentiate mechanisms
for cytoprotective APC signaling vs. proinflammatory thrombin signaling
(Zlokovic and Griffin, 2011; Griffin et al., 2015). Additional mechanisms for
APC effects on cells may also involve other receptors, such as PAR-3,
sphingosine-1-phosphate receptor 1, apolipoprotein E Receptor 2, and/or
Mac1 (CD11b/CD18). For example, the beneficial actions of APC or
3K3A-APC on middle cerebral artery occlusion (MCAO) injury required PAR-1,
EPCR, and PAR-3 (Cheng et al., 2003, 2006; Guo et al., 2004, 2013;
Thiyagarajan et al., 2008; Gorbacheva et al., 2010; Petraglia et al., 2010;
Zlokovic and Griffin, 2011) and stimulation of development of neurons within
human neuroprogenitor cell populations required PAR-1, PAR-3, and
sphingosine-1-phosphate receptor 1 (Guo et al., 2013).
BBB Preservation
The vasculoprotective effects of APC include PAR1-mediated
activation of sphingosine kinase-1 which leads to activation
of Rac1, a member of the Rho family of GTPases, and
the rearrangement of the endothelial cytoskeleton. By
stabilizing BBB integrity and attenuating post-ischemic BBB
breakdown, APC prevents secondary neuronal injury due to
the accumulation of blood-derived neurotoxic and vasculotoxic
molecules such as fibrin, hemosiderin, thrombin, and plasmin
(Zlokovic and Griffin, 2011).
APC also downregulates nuclear translocation of nuclear
factor kappa B (NF-κB), thus blocking NF-κB dependent
transcriptional activation of matrix metalloproteinase-9
(MMP-9). This molecule and other proteinases are responsible
for post-ischemic degradation of the basement membrane
proteins of the BBB, leading to intracerebral hemorrhage, an
effect that is potentiated by tPA. In murine ischemic stroke
models of MCAO, APC reduced tPA-induced intracerebral
hemorrhage through its actions on PAR1 and reduced MMP9
expression (Cheng et al., 2006).
Additionally, APC blocks apoptosis of endothelial cells
by inhibiting mitochondria-mediated caspase-9-dependent
pathways, upregulating anti-apoptotic genes, suppressing p53
pro-apoptotic pathways, and other mechanisms (Cheng et al.,
2003). Lastly, APC stimulates angiogenesis from endothelial cells
in both in vivo and in vitro models, leading to the formation
of new capillaries that can provide the nourishment for an
environment conducive to neuroregeneration (Zlokovic and
Griffin, 2011).
Suppression of Neuroinflammation
APC inhibits transport of neutrophils and monocytes across
the BBB, thereby blocking early post-ischemic infiltration of the
brain by leukocytes. It also suppresses microglia activation. These
effects are mediated by suppressing NF-κB dependent expression
of proinflammatory cytokines such as tumor necrosis factor–α,
interleukins, and vascular adhesion molecules (Zlokovic and
Griffin, 2011).
Neuroprotection
APC and its analogs cross the BBB via EPCR-dependent
transport to reach neuronal targets and exert direct neuronal
protection (Deane et al., 2009), as demonstrated in murine
N-Methyl-D-aspartate (NMDA) excitotoxic injury models in
vivo and in cultured neurons in vitro (Guo et al., 2004;
Gorbacheva et al., 2010). Furthermore, as it does in endothelial
cells, APC inhibits the intrinsic, caspase-9 dependent and
p-53 mediated proapoptotic pathways and upregulates anti-
apoptotic genes in neurons, too (Guo et al., 2004). Importantly,
the therapeutic window of APC for stroke is much wider
than that for tPA. Preclinical models demonstrate that APC
is neuroprotective even when first administered 12 h after
permanent MCAO or 24 h after transient MCAO (Guo
et al., 2004; Wang et al., 2009). One key element for APC’s
neuroprotection is its ability to signal activation of the Akt-
survival pathways.
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Neuroregeneration
In addition to its neuroprotective effects, APC has been shown
to promote post-ischemic neurogenesis in the mouse brain
and in human embryo-derived neuroprogenitor cell cultures
where activation of the Akt pathway is required (Thiyagarajan
et al., 2008; Guo et al., 2013). These effects involve increased
proliferation of neuronal progenitor cells of the subventricular
zone and increased migration of neuroblasts from this area
towards the ischemic border. Similar effects on neurogenesis
were shown when APC was used in preclinical models of
traumatic brain injury (Petraglia et al., 2010).
Rationale for Combining
Neurothrombectomy and Adjunctive APC
Untreated cerebral thrombosis is associated with high rates of
morbidity and mortality. For instance, among patients with
persistent proximal vessel in the anterior circulation, up to 80%
die within 90 days of stroke onset or fail to regain functional
independence (Goyal et al., 2015). Timely restoration of blood
flow to the ischemic territory improves clinical outcome by
salvaging the hypoperfused tissue at risk of infarction. Indeed,
meta-analysis of several studies confirms the strong correlation
between recanalization and outcome in AIS; the odds ratio of
functional independence or death for those with recanalization
compared to those without is 4.43 and 0.24, respectively (Rha and
Saver, 2007). Similarly, for every 30 min delay in reperfusion, the
likelihood of favorable outcome decreases by 10% (Khatri et al.,
2009), as it is estimated that for each minute during acute stroke,
1.9 million neurons, 14 billion synapses, and 12 km (7.5 miles) of
myelinated fibers are destroyed (Saver, 2006).
However, the premise that underlies this notion, the
‘‘recanalization hypothesis’’, has been repeatedly contested (von
Kummer et al., 1995; Rha and Saver, 2007). Analysis of the
reasons behind this challenge reinforces the benefit of a strategy
combining neurothrombectomy with adjunctive delivery of
APC (Table 2). Adding APC to neurothrombectomy should
strengthen the biological relationship between recanalization and
outcome.
Firstly, recanalization of upstream large arteries is not
always tantamount to tissue reperfusion distal to the occlusion.
Rethrombosis, migration of emboli, secondary thrombosis of
downstream arteries, or microcirculatory occlusion may produce
a no-reflow phenomenon despite proximal vessel opening (Bai
and Lyden, 2015). The inherent antithrombotic activity of
APC might mitigate the deleterious clotting that underlies no-
reflow. Conversely, excessive anticoagulation might promote
intracerebral bleeding. APC variants such as 3K3A-APC,
which have reduced anticoagulant activity compared with wild
type, might represent a favorable compromise between these
prothrombotic and anticoagulant forces, but this remains to be
proven in human subjects.
Secondly, restoration of flow to ischemic brain tissue
may risk reperfusion injury, hemorrhagic transformation, or
cerebral edema, which could also counteract the theoretical
benefit of recanalization. By repairing the integrity of the
damaged BBB within the ischemic tissue, adjunctive APC confers
vasculoprotective benefits.
Next, some recanalization therapies such as tPA have
intrinsic neuorotoxicity through induction of caspases and other
proapoptotic pathways, as well as or through breakdown of the
BBB leading to the toxic accumulation of serum proteins that
effect secondary neuronal injury (del Zoppo, 1998; Liu et al.,
2004; Zlokovic and Griffin, 2011). The neuroprotective actions
of APC might overcome this damage.
Lastly, recanalization may occur too late to benefit ischemic
tissue that has already progressed to infarction. The neurogenic
and angiogenic properties of APC, confirmed in both in vitro
and in vivo models, might contribute to functional recovery and
improved clinical outcome in such scenarios.
Current Protocols and Future Directions
The ‘‘Safety Evaluation of 3K3A-APC in Ischemic Stroke
(RHAPSODY)’’ trial (NCT02222714, NN104) is a multicenter,
prospective, double-blinded, dose-escalation Phase 2 RCT.
It intends to assess the safety, pharmacokinetics and efficacy
of 3K3A-APC following treatment with tPA, mechanical
neurothrombectomy, or both (for subjects undergoing
neurothrombectomy, onset time to arterial puncture must
be <6 h). Four different doses of 3K3A-APC are being tested to
establish the maximum tolerated dose. Eligibility criteria include
age 18–90 and NIHSS ≥5. The trial started in October 2014 and
will enroll up to 100 subjects.
Prior studies in sepsis have shown that low-dose continuous
infusion of APC is not optimally suited to harness its cell
signaling actions and that bolus dosingmore effectively promotes
the receptor activation that leads to altered gene expression
TABLE 2 | Challenges to the “recanalization hypothesis” and rationale for adjunctive APC.
Recanalization problem APC solution
No reflow phenomenon due to rethrombosis, migration of emboli, Antithrombotic activity
secondary thrombosis of downstream arteries, or microcirculatory occlusion
Reperfusion injury, hemorrhagic transformation, or cerebral edema, Vasculoprotective effects on BBB integrity
Neurotoxicity Neuroprotection
Recanalization occurs too late Neurogenesis and Angiogenesis
The potential explanations for poor clinical outcome despite reopening of occluded vessels and the beneficial properties of APC that redress each of these pitfalls are
summarized.
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profiles and the salutary effects of BBB stabilization and of anti-
apoptic and anti-inflammatory activities (Griffin et al., 2015).
For this reason, the RHAPSODY protocol employs a regimen
of intravenous APC bolus doses every 12 h, up to a total of
five doses. The previous Phase 1 safety study in normal subjects
confirmed that high dose bolus regimens using 3K3A-APC are
safe (Lyden et al., 2013).
In the future, consideration can be given to direct
intra-arterial administration of APC at the time of
neurothrombectomy. When given through a microcatheter
that has been navigated past the occlusion, intra-arterial
injection can achieve better and more reliable delivery to the
affected territory, even if the proximal vessel subsequently
re-occludes and there is no recanalization. The intra-arterial
delivery of APC after neurothrombectomy exemplifies the
concept of endovascular restorative neurosurgery (ERN)
that we previously advanced (Amar et al., 2003). Theoretic
advantages of ERN with intra-arterial drug delivery include
the possibility of widespread distribution, the capability to
deliver large volumes and doses to target tissue relative to IV
infusion, the ability to bypass the occlusive lesion and access
territory not perfused by collateral flow, limited perturbation
of neural tissue, and the feasibility of repeated administration
(Amar et al., 2003). The relatively high dose of drugs like
APC that can be delivered intra-arterially via ERN strategies
support the biological rationale for this approach (Amar et al.,
2003).
Conclusion
An approach that couples mechanical neurothrombectomy
with adjunctive delivery of a multiple action—multiple target
drug offers many advantages over conventional treatment of
AIS. The anti-inflammatory, anti-apoptotic, neuroprotective,
and neuroregenerative properties of APC make this agent a
compelling candidate for this strategy. While current protocols
employ intravenous delivery of this agent, future studies of intra-
arterial delivery are warranted.
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